299 results about "Jejunum" patented technology

Method for treating a Roux-en-Y patient having fistulas and leaks as a result of bariatric surgery. A gastrointestinal implant device is anchored in the esophagus and extends through a stomach pouch into an intestine anastomosed to the stomach pouch to prevent fistulas and other damaged tissue from making contact with food and fluids entering the esophagus. The gastrointestinal implant device includes an unsupported flexible sleeve and an anchor coupled to a proximal portion of the sleeve. The flexible sleeve is open at both ends, and adapted to extend below a jejunum. The anchor is adapted to be retained within the esophagus, preferably just above the gastroesophageal (GE) Junction. The anchor can include a stent such as a wave anchor and is collapsible for catheter-based delivery and removal.

A gastrointestinal implant device is positioned in a patient's small intestine or rectum and produces an outward force that itself produces a distension signal which is a therapeutically useful neural or humoral signal that evokes satiogenic or weight loss effects by itself. The device may advantageously be placed in the duodenum adjacent the pylorus or in the jejunum, ileum or rectum. The distension signals may amplify chemosensory or mechanosensory signals such as enteroendocrine secretions within the patient. The device may be a mesh and include a low material density that allows for unrestricted chyme absorption within the small intestine and unrestricted chyme flow through the gastrointestinal system. A method includes inserting the device into the patient then either retrieving the device after treatment is complete or allowing a device formed of a biodegradable material to degrade in time after treatment is complete.

Oral formulations of pharmaceuticals are provided with enhanced bioavailability by targeting specific regions of the gastrointestinal tract. Particularly, water soluble and acid-labile drugs such as cytidine analogs (e.g., decitabine) and 2'-deoxyadenosine analogs (e.g., pentostatin) are formulated with pH-sensitive polymers so that these drugs are preferably absorbed in the upper regions of the small intestine, such as the jejunum. In addition, drugs with poor oral bioavailability such as camptothecin compounds (e.g., 9-nitro-camptothecin) can also be formulated using similar strategies in order to significantly improve their oral bioavailability. These formulations can be used to treat a wide variety of diseases or conditions, such hematological disorders, benign tumors, cancer, restenosis, inflammatory diseases, and autoimmune diseases.

Devices and methods for deploying an anastomotic stent between portions of the gastro-intestinal (GI) tract are disclosed. The anastomotic stents are configured to atraumatically engage the tissue walls and to permit the flow of fluid, partially digested food, and food. The stents can be deployed using endoscopic catheter devices, laparoscopic tools, and combinations of both endoscopic tools and laparoscopic tools. Examples of anastomoses include anastomoses between the stomach and a portion of the intestines such as the jejunum. Anastomoses can also be formed between two closed ends of the intestines, such as two closed ends of the colon formed during a colon resection procedure. Anastomoses can also be formed between a fundal pouch formed during a gastric bypass procedure and the jejunum. Laparoscopic tools are disclosed to deploy a stent by selectively removing a radial restraint on a self expanding stent with the restraint removed through the laparoscopic access points.

The present invention is directed generically to a means for altering the ability of the mammalian body to absorb nutritive content from ingested foodstuffs, and more specifically to an apparatus and method of use for an endolumenal sleeve (referred to also as an “intragastrointestinal device” or “gastrointestinal device”) positioned in the mammalian gastrointestinal (GI) tract. A suitable endolumenal sleeve is comprised of an anchor element and an opening at a proximal end, an elongate lumen or hollow open-ended tube having a transverse dimension, and a distal orifice. Optionally, an exterior aspect of the elongate lumen may include additional modes of attachment to the tissues walls of the GI tract through the use of one or more means for promoting tissue in-growth. The endolumenal sleeve is retained in the GI tract such that a substantial fraction of the food and liquids passing through the GI tract is channeled into the proximal opening and through an interlumenal space defined within the interior space of the endolumenal sleeve. Within the endolumenal sleeve there may be one or more restrictive means to constrain, impede or otherwise control the operative flow of material through the device. An individual restrictive means can either be of a fixed geometry or such means may include one or more elements which are adjustable in nature or function. The elongate lumen of the endolumenal sleeve is formed of a polymer composition suitable for controlled ingress of biological secretions, egress of certain selected nutritional elements, and may comprise either a single tubular structure or a multi-section (i.e. articulated and/or multiple lumen) assembly. When the endolumenal sleeve is in situ within the mammalian gastro-intestinal system, ingested foodstuffs are conveyed from the proximal end to said distal orifice. In typical applications, the proximal end of the endolumenal sleeve is positioned within the physiological region extending from the lower esophagus to the duodenum and the distal orifice is positioned within the physiological region extending from the upper duodenum to the lower jejunum, though further extension into the lower intestine is possible. Through proper selection of position for the endolumenal sleeve proximal and distal ends, combined by selection of the composition used in the fabrication of the elongate lumen, it is possible to finitely control the degree of nutritive absorption performed by the gastrointestinal tract.

The invention relates to lactobacillus plantarum CCFM8724 and application thereof. The lactobacillus plantarum CCFM8724 has ability of suppressing growth of campylobacter jejuni in vitro, good resistance to acid and cholate and good adhesive ability to intestinal epithelial cells, and can control the campylobacter jejuni adhering to the intestinal epithelial cells so as to suppress growth of the campylobacter jejuni in chicken. The lactobacillus plantarum CCFM8724 can be used for preparing a medicinal composition for suppressing campylobacter jejuni; a fermentation agent containing the strain of lactobacillus plantarum CCFM8724 can be used for producing fermented dairy products, fermented bean products, fermented fruit/vegetable products and silage; the fermentation agent enables the products to obtain certain acidity and particular flavor; and meanwhile, the product preserving time is prolonged, and the nutritional value, digestibility and safety of the products are improved.

An improved process using electrostimulation for treating obesity, especially morbid obesity, is provided. The improved method of this invention provides electrostimulation on or along the small intestines, preferably on or along the duodenum and/or jejunum, which provides improved control of obesity. In one embodiment, the process employs stimulation of the lesser curvature at a rate of about 2 to about 30 pulses/minute with each pulse lasting about 0.1 to about 4 seconds such that there is a pause of about 3 to about 30 seconds between the pulses. More preferably, the pulse rate is about 12 to about 14 pulses/minute with each pulse lasting about 0.1 to about 0.5 seconds with a pause of about 4.5 to about 5 seconds between pulses. Preferably, the pulse amplitude is about 0.5 to about 15 milliamps. More preferable, each pulse consists of a train of micro-bursts with a frequency of about 5 to about 100 Hz.

Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be substantially stable in gastric fluid and substantially unstable in intestinal fluid, thus providing for substantial release of the tight junction agonist and/or antagonist from the composition in the duodenum or jejunum of the small intestine.

The present embodiments provide medical apparatuses, systems, and methods for rapidly forming an anastomosis between two viscera. The medical apparatus generally comprises two bases with two clamp members rotatably attached to the bases, the clamp members being capable of compressing tissue. The system generally comprises positioning and then deploying the medical apparatus between and within two stomas via an elongate member. The method generally comprises using the medical system to create an anastomosis between the stomach and the jejunum.

A controlled release composition comprising nimesulide as an active agent formulated as a gastroretentive system, preferably as a solid oral dosage form is provided, wherein the residence time of the active agent is increased in the stomach, duodenum, jejunum or ileum. The present invention also provides process of preparing such dosage form and methods of using such dosage form compositions. The dosage form compositions are preferably administered once-a-day or twice-a-day and are particularly very useful in the prophylaxis or treatment of NSAID indicated disorder(s) such as acute painful conditions like post-operative trauma, pain associated with cancer, sports injuries, migraine headache and the like, or chronic diseases such as arthritis and the like.

With a first endoscope inserted through an overtube, the overtube is orally inserted into an object being examined, and a distal end portion of an insertion tube of the first endoscope is made to advance, within the object, from a jejunum via a jejunum-to-jejunum anastomosed portion and a jejunum-anastomosed bent portion so that the distal end portion is located adjacently to a Vater's papilla of a duodenum. The overtube is then sent to a position which is adjacent to the Vater's papilla along the insertion tube of the first endoscope. After this, the first endoscope is pulled from the overtube. A second endoscope is then inserted into the overtube to make a distal end portion of its insertion tube protrude from the distal end of the overtube and is located adjacently to the Vater's papilla. The second endoscope thus-approached is used to treat the Vater's papilla and the tissue therearound.

An feeding tube and a kit for installation of a feeding tube includes a balloon anchored gastric tube. A protective sleeve on a dilator protects the toroidal balloon from damage during surgical insertion of the feeding tube. In one example, a jejunal tube is integrated with the kit and the gastric tube serves as a gastric sleeve forming an annular region or channels for fluid flow to and/or from the stomach and to/from the jejunum. An integrated gastro jejunal feeding tube unit may include a jejunal tube outlet port at one end, a jejunal balloon port, a gastric sleeve outlet port, one or more gastric balloon ports, one or more gastric balloons, gastric drainage holes, a jejunal balloon positioned at end of the jejunal tube and sleeve. A black silk loop may affix an end of the jejunal tube at a position in the jejunum, and insertion of the jejunal tube may be monitored continuously using an endoscope. Drainage holes may be provided in the jejunal tube and/or the gastric sleeve. Depending on the clinical state, feeding may be initiated through the gastric sleeve outlet port or via the jejunal tube outlet port and may be altered without surgical intervention, as required. Drainage holes in the gastric sleeve may be used to deflate the stomach, while nutrition is provided by a jejunal tube inserted in the jejunum, simultaneously.

The invention discloses an oligonucleotide primer for detecting common pathogenic bacteria by adopting a fluorescent quantitation PCR (Rich Client Platform) technology, a method thereof for detecting common pathogenic bacteria and the application thereof. The method comprises the following steps of: providing 10 pairs of specific oligonucleotide primer sequences at annealing temperature of 50-60 DEG C without differing 5 DEG C; and simultaneously, quickly, accurately and effectively identifying and quantificationally detecting various pathogenic bacteria at the same time. A detection range comprises bacillus cereus, enterobacter sakazakii, vibrio parahaemolyticus, enterohemorrhagic escherichia coli O157, salmonella, Listeria monocytogenes, Shigella, campylobacter jejuni, pseudomonas aeruginosa, klebsiella pneumoniae, and the like. The invention also can be used for the fields of disease diagnosis, environmental monitoring, water-quality and food supervision and detection, food poisoning pathogenicbacteria detection, bacteriological classification, epidemiological investigation, biological agent detection, and the like, is convenient, quick, accurate and effective and has wide application range.

The present invention provides a gene chip for quickly detecting pathogens from food source, discloses the preparation method of said gene chip and provides 26 oligonucleotide probe sequences for detection. Said gene chip can quickly, accurately and high-effectively detect and identify the class of the pathogens in food, and its detection range includes staphylococcus aureus, Shiga's bacillus, salmonella, colibacillus 0157, bacillus proteus, mononuclear hyperplastic listerella, enterocolitis yersinia, aeruginous pseudomonads, vibrio parahaemolyticus, vibrio cholerae, bacillus cereus, beta hemolytic streptococcus, coconut fermentation pseudomonads, boticin, vibrio jejuni and bacillus perfringens, etc.

Abstract of the Disclosure A prebiotic, composition comprising a probiotic and prebiotic, and method of delivering a probiotic, prebiotic or composition directly into the intestinal tract of a mammal are disclosed. The probiotic is any beneficial bacteria and the prebiotic is a substance beneficial to a probiotic. Most preferably, the prebiotic includes a mucopolysaccharide. The method preferably involves delivering the probiotic, prebiotic or composition via a delivery tube, such as an enteral feeding tube, directly to a position downstream of the stomach, most preferably to the jejunum.

The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.